The Board of Pharmacy has received notice of the following product withdrawal:

Description	Lot #	NDC	UPC
BELVIQ TAB 10MG 60	All Lots	62856052960	36285652960
BELVIQ XR TAB 20MG 30	All Lots	62856053530	36285653530

Eisai is withdrawing the above items based on recently completed analysis of data from the Camellia-Timi 61 trial, concluding that the potential risks of the product outweigh its benefits. This recall is to the consumer level.

The Board of Pharmacy strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.